MetaVision Study
Research type
Research Study
Full title
Real-life prospective evaluation of computer-aided detection (CAD) of Barrett’s neoplasia: MetaVision Study
IRAS ID
319708
Contact name
Pradeep Bhandari
Contact email
Sponsor organisation
Portsmouth Hospitals University NHS Trust
Duration of Study in the UK
1 years, 5 months, 31 days
Research summary
Barrett’s oesophagus is a pre-cancerous condition in which normal cells in the gullet lining undergo cell changes and this increases the risk of developing cancer of the gullet. This type of cancer is the 5th most common type of cancer in the UK. To minimise this risk of developing cancer, patients with Barret’s oesophagus have a regular gastroscopy every 2-5 years to detect early cancer cell changes. During the procedure, the whole of oesophagus is carefully inspected and targeted biopsies are taken from visible abnormal area within Barrett’s oesophagus and sent to the lab to check for cell changes. As the endoscopist cannot always tell during gastroscopy where cells are changing, biopsies from each quarter of the gullet (called quadrantic biopsies) are also taken to reduce the risk of pre-cancerous cells being missed. However, this process is time consuming and expensive.
Recently, there has been a huge development in artificial intelligence. One of these developments is the aid of computer to detect the abnormal cell changes within Barrett’s during gastroscopy. This system has recently been tested on videos and images to prove that its performance is as good as expert endoscopists. This system has been already approved to use in the UK. However, we need to test this system in real-life use to prove that the system is useful in detecting abnormal cell changes during gastroscopy for targeted biopsies and therefore, the quadrantic random biopsies can be avoided.
Patients with Barrett’s oesophagus will be invited to participate in this study. Participants will have a gastroscopy as part of their usual care. Endoscopist will inspect Barrett’s oesophagus using the system and will take targeted biopsies if clinically deemed appropriate along with quadrantic biopsies. Participants will continue to receive usual care and no additional follow-up or procedures will be required for the study.REC name
London - Bromley Research Ethics Committee
REC reference
23/PR/0213
Date of REC Opinion
5 Jun 2023
REC opinion
Further Information Favourable Opinion